BioSpace News Archive

Curaleaf Holdings, Inc. announced its management will participate in the following institutional investor conferences in June 2019.

Brain Balance Achievement Centers, the leading drug-free program designed to improve focus, behavior, social skills, anxiety and academic performance, announced today that its Vice President of Outcomes and Programs, Dr. Rebecca Jackson, has been invited to speak at the 4th Annual Brain Disorders, Neurology and Therapeutics conference

LPIXEL Inc., a leader in image analysis and processing technology in life science and medical research, is pleased to announce the initiation of the artificial intelligence (AI) system development for cell evaluation with Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”).

Celgene Corporation (NASDAQ: CELG) today announced that data from the TRANSCEND CLL 004 and TRANSCEND NHL 001 trials studying the investigational anti-CD19 chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel; JCAR017) in patients with B-cell blood cancers were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Zymo Research recently received recognition and appreciation from the National Aeronautics and Space Administration’s Human Research Program for their support and involvement in the development of a specialized DNA/RNA Shield™ Swab Collection Device.

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from the Phase III NALA trial of PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease) in the setting of metastatic disease, were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago.

Mobile Health Assessment is the First National Laboratory Service Available to Consumers in their Home or Office

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the pivotal Phase III CLL14 study in previously untreated chronic lymphocytic leukemia (CLL) showing that Venclexta® (venetoclax) plus Gazyva® (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival (PFS).

The Personal Connected Health Alliance, a HIMSS innovation company, announced that the 2019 Connected Health Conference will return to Boston, October 16-18.

CQDM is pleased to announce that following their recent enrollment in the consortium, Amgen and Takeda will be joining the syndicate of pharma companies to fund the Quantum Leap project recently launched by Feldan Therapeutics (Feldan)